<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="[18F]FB-IL-2 PET Imaging to Assess the Immunopathogenicity of O'nyong-nyong Virus" exact="Infection" post="ChanYi-Hao12TeoTeck-Hui1â€ Torres-RuestaAnthony13HartimathSiddesh V.4CheeRhonda Sin-Ling1KhanapurShivashankar4YongFui Fong4RamasamyBoominathan4ChengPeter4RajarethinamRavisankar5RobinsEdward G.46GoggiJulian L.4LumFok-Moon1â€ CarissimoGuillaume1RÃ©niaLaurent12NgLisa F."/>
 <result pre="Lin School of Medicine, National University of SingaporeSingaporeSingapore[], 7Institute of" exact="Infection" post="and Global Health, University of LiverpoolLiverpoolUnited Kingdom Edited by:"/>
 <result pre="Lisa F. P. Ng lisa_ng@immunol.a-star.edu.sg This article was submitted to" exact="Viral" post="Immunology, a section of the journal Frontiers in Immunology"/>
 <result pre="donors conducted in 2019 revealed high rates of unreported ONNV" exact="infection" post="in Uganda. Due to similar clinical symptoms with other"/>
 <result pre="symptoms with other endemic mosquito-borne pathogens in the region, including" exact="chikungunya" post="virus, dengue virus and malaria, ONNV infections are often"/>
 <result pre="the region, including chikungunya virus, dengue virus and malaria, ONNV" exact="infections" post="are often un- or misdiagnosed. Elucidating the immunopathogenic factors"/>
 <result pre="an immune competent C57BL6/J mouse model to mechanistically characterize ONNV" exact="infection" post="and assess potential treatment efficacy. This mouse model successfully"/>
 <result pre="immune competent ONNV model for future studies on factors influencing" exact="disease" post="pathogenesis, which could shape the discovery of novel therapeutic"/>
 <result pre="virus (ONNV) is a mosquito-borne arthritogenic alphavirus. ONNV-infected patients display" exact="acute" post="clinical symptoms of low-grade fever, self-limiting polyarthralgia, and other"/>
 <result pre="acute clinical symptoms of low-grade fever, self-limiting polyarthralgia, and other" exact="disease" post="manifestations like lymphadenopathy, generalized maculopapular skin rash, and rare"/>
 <result pre="like lymphadenopathy, generalized maculopapular skin rash, and rare occurrences of" exact="bleeding" post="gums and nosebleeds (1, 2). There are also cases"/>
 <result pre="ONNV cases are often underestimated and misdiagnosed for other endemic" exact="infectious diseases" post="with more pronounced, overlapping symptoms, such as chikungunya virus"/>
 <result pre="endemic infectious diseases with more pronounced, overlapping symptoms, such as" exact="chikungunya" post="virus (CHIKV), dengue virus (DENV) or malaria. ONNV has"/>
 <result pre="of people (1, 4â€&quot;6). Antibody-based serological assays highlighted the nearly" exact="complete" post="cross-reactivity between CHIKV and ONNV (6â€&quot;8), hindering proper detection"/>
 <result pre="particularly to ONNV and closely-related CHIKV (4, 9, 10). The" exact="absence of" post="epidemiological data on transmission levels in Africa and other"/>
 <result pre="global spread. Currently, the components of host immunity mediating ONNV" exact="disease" post="are poorly understood. Establishing a mouse model which recapitulates"/>
 <result pre="C57BL6/J mouse model, which upon ONNV infection, presents a self-limiting" exact="disease" post="with peak viremia at 3 days post-infection (dpi) and"/>
 <result pre="therapeutic strategy to inhibit CD4+ T cell infiltration and abrogate" exact="joint swelling." post="The development of this mouse model will prove essential"/>
 <result pre="France) (11). Virus isolation was attempted by incubation of patient" exact="peripheral" post="blood mononuclear cells collected on day of illness onset"/>
 <result pre="on a 20% (w/v) sucrose-cushion ultracentrifugation to produce the ONNV" exact="infection" post="stock used in mice, as previously described (12). Infection"/>
 <result pre="ONNV infection stock used in mice, as previously described (12)." exact="Infection" post="stock titers were determined by standard plaque assay using"/>
 <result pre="by standard plaque assay using Vero E6 cells, with a" exact="viral" post="RNA/PFU ratio of 1440. Firefly luciferase (Fluc)-tagged ONNV infectious"/>
 <result pre="a viral RNA/PFU ratio of 1440. Firefly luciferase (Fluc)-tagged ONNV" exact="infectious" post="clone (ONNV-Fluc), with the Fluc gene inserted between the"/>
 <result pre="Advisory Committee for Laboratory Animal Research of Singapore (NACLAR). Virus" exact="Infection" post="and Disease Evaluation Mice were inoculated subcutaneously with 106"/>
 <result pre="for Laboratory Animal Research of Singapore (NACLAR). Virus Infection and" exact="Disease" post="Evaluation Mice were inoculated subcutaneously with 106 plaque forming"/>
 <result pre="daily for 2-weeks, and quantified as (Height Ã— breadth). The" exact="disease" post="score was then expressed as the relative fold change"/>
 <result pre="change in foot size compared with the same foot before" exact="infection" post="(0 dpi) using the following formula: [(x â€&quot;0 dpi)/0"/>
 <result pre="x is the quantified footpad measurement for each respective day." exact="Viral" post="RNA Extraction and Viral Copies Quantification Ten microliters of"/>
 <result pre="footpad measurement for each respective day. Viral RNA Extraction and" exact="Viral" post="Copies Quantification Ten microliters of blood were obtained from"/>
 <result pre="PBS supplemented with 10 Î¼l of citrate-phosphate-dextrose solution (Sigma-Aldrich). The" exact="viral" post="RNA in the blood samples were purified by QIAamp"/>
 <result pre="viral RNA in the blood samples were purified by QIAamp" exact="Viral" post="RNA kit (Qiagen), according to the manufacturer's protocol. Viral"/>
 <result pre="QIAamp Viral RNA kit (Qiagen), according to the manufacturer's protocol." exact="Viral" post="RNA is eluted in 60 Î¼l of elution buffer."/>
 <result pre="Viral RNA is eluted in 60 Î¼l of elution buffer." exact="Viral" post="load in 1 Î¼l of the elution buffer was"/>
 <result pre="qRT-PCR using QuantiTect Probe RT PCR kit (Qiagen). For ONNV" exact="viral" post="genome quantification, the following primers were designed to amplify"/>
 <result pre="quantification, the following primers were designed to amplify negative nsP1" exact="viral" post="RNA: forward primer (AATTACGCGAGAAAACTTGCG), reverse primer (TTTTTCCAGAGATGTTTTTATCTGT) and TaqMan"/>
 <result pre="min. Data collection occurred during the 55Â°C extension step (15)." exact="Mouse" post="Joint Cell Isolation ONNV-infected mice were euthanized at 6"/>
 <result pre="Data collection occurred during the 55Â°C extension step (15). Mouse" exact="Joint" post="Cell Isolation ONNV-infected mice were euthanized at 6 dpi."/>
 <result pre="solution. Samples were then washed and resuspended in 2 ml" exact="complete" post="RPMI medium, and overlaid onto 1 ml 35% v/v"/>
 <result pre="rpm for 20 min. Cells were washed and resuspended in" exact="complete" post="RPMI before counting with hemocytometer (16). Phenotyping of Leukocytes"/>
 <result pre="counting with hemocytometer (16). Phenotyping of Leukocytes by Flow Cytometry" exact="Isolated" post="cells were incubated with blocking buffer containing 1% rat"/>
 <result pre="was performed on 0, 4, and 6 days after ONNV" exact="infection" post="using a Siemens Inveon PET-CT. Briefly, animals were sedated"/>
 <result pre="(clone 17A2; BioLegend)] before ONNV inoculation (0 dpi). Mice with" exact="incomplete" post="depletion of CD4+ T cells were administered with another"/>
 <result pre="the drug daily from 2 to 6 dpi. Quantification of" exact="Joint" post="Vascular Leakage by Tracer Assay Tracer 653 Assay (Molecular"/>
 <result pre="drug daily from 2 to 6 dpi. Quantification of Joint" exact="Vascular" post="Leakage by Tracer Assay Tracer 653 Assay (Molecular Targeting"/>
 <result pre="was then quantified with in vivo imaging system (IVIS) (PerkinElmer)." exact="Vascular" post="leakage in regions of interest were quantified using Living"/>
 <result pre="and DP manager software. Histo-pathological assessments were performed in a" exact="blind" post="fashion by histo-pathologist, using a scoring method in each"/>
 <result pre="each individual animal based on the presence of edema, inflammation," exact="muscle" post="necrosis, tendonitis and synovitis, if any. Severity of the"/>
 <result pre="animal based on the presence of edema, inflammation, muscle necrosis," exact="tendonitis" post="and synovitis, if any. Severity of the lesions were"/>
 <result pre="of edema, inflammation, muscle necrosis, tendonitis and synovitis, if any." exact="Severity of" post="the lesions were assigned to the following scale: 0â€&quot;no"/>
 <result pre="optimize an in vivo pre-clinical model for ONNV, one million" exact="infectious" post="ONNV particles were subcutaneously inoculated into the right-hind joints"/>
 <result pre="2). Notably, 3-week-old mice suffered from significantly higher levels of" exact="viral" post="load in the peripheral blood compared to 6WO mice."/>
 <result pre="suffered from significantly higher levels of viral load in the" exact="peripheral" post="blood compared to 6WO mice. At 6 days post-infection"/>
 <result pre="mice are a more consistent model for investigating in vivo" exact="viral" post="resolution (Figure 1A). To confirm that viremia in the"/>
 <result pre="resolution (Figure 1A). To confirm that viremia in the early" exact="acute" post="phase was representative of viral replication instead of inoculum"/>
 <result pre="that viremia in the early acute phase was representative of" exact="viral" post="replication instead of inoculum decay, we constructed a ONNV"/>
 <result pre="replication instead of inoculum decay, we constructed a ONNV reporter" exact="infectious" post="clone carrying a Firefly luciferase gene expressed only during"/>
 <result pre="luciferase gene expressed only during replication (24). This confirms that" exact="viral" post="replication can be observed as early as 6 h"/>
 <result pre="ONNV-infected joints up to 40 dpi, which is similar to" exact="CHIKV infection" post="(16). Figure 1 ONNV infection in wild-type C57BL/6 mice"/>
 <result pre="joints up to 40 dpi, which is similar to CHIKV" exact="infection" post="(16). Figure 1 ONNV infection in wild-type C57BL/6 mice"/>
 <result pre="which is similar to CHIKV infection (16). Figure 1 ONNV" exact="infection" post="in wild-type C57BL/6 mice resulted in virus replication and"/>
 <result pre="in virus replication and joint pathology. (A) Viremia and (B)" exact="joint swelling" post="of ONNV-infected mice aged 3-weeks-old (3WO, n = 13)"/>
 <result pre="(H&amp;amp;E) images of inflamed joint footpad on 6 dpi. The" exact="muscle" post="area (M) shows presence of muscle degeneration (D) and"/>
 <result pre="on 6 dpi. The muscle area (M) shows presence of" exact="muscle" post="degeneration (D) and necrosis (N) upon ONNV infection. Blue"/>
 <result pre="(E) Severity scores were assigned for myopathy, including edema and" exact="muscle" post="degeneration and necrosis, and inflammation at the muscle, synovial"/>
 <result pre="inflamed joints indicated by yellow arrows, and quantification of joint" exact="vascular" post="leakage into the joints of ONNV-infected and PBS control"/>
 <result pre="Mann Whitney U-test. ONNV-infected joints developed a mild, yet visible" exact="joint swelling" post="around the metatarsal region that peaked on 6 dpi"/>
 <result pre="region that peaked on 6 dpi (Figures 1B,C). Importantly, peak" exact="joint swelling" post="was significantly more pronounced for the 3WO group (Figures"/>
 <result pre="ONNV as it recapitulates most of the clinical symptoms. ONNV" exact="Infection" post="Induces Muscle Damage and Infiltration of Inflammatory Cells Histopathological"/>
 <result pre="it recapitulates most of the clinical symptoms. ONNV Infection Induces" exact="Muscle" post="Damage and Infiltration of Inflammatory Cells Histopathological analyzes in"/>
 <result pre="clinical symptoms. ONNV Infection Induces Muscle Damage and Infiltration of" exact="Inflammatory" post="Cells Histopathological analyzes in the ONNV-infected joint, performed on"/>
 <result pre="analyzes in the ONNV-infected joint, performed on the peak of" exact="joint swelling" post="(6 dpi), revealed the presence of marked muscle degeneration"/>
 <result pre="of joint swelling (6 dpi), revealed the presence of marked" exact="muscle" post="degeneration and necrosis, mild synovitis at the synovium, and"/>
 <result pre="revealed the presence of marked muscle degeneration and necrosis, mild" exact="synovitis" post="at the synovium, and tenosynovitis around the tendon capsule"/>
 <result pre="muscle degeneration and necrosis, mild synovitis at the synovium, and" exact="tenosynovitis" post="around the tendon capsule (Figures 1D,E). There were also"/>
 <result pre="ONNV infected joints (Figures 1D,E). This observation suggests that the" exact="joint swelling" post="was not due to vascular leakage but contributed by"/>
 <result pre="observation suggests that the joint swelling was not due to" exact="vascular" post="leakage but contributed by the tissue damage in the"/>
 <result pre="by the tissue damage in the joints. To validate the" exact="absence of" post="vascular leakage in ONNV-infected joints, tracer assay and in"/>
 <result pre="tissue damage in the joints. To validate the absence of" exact="vascular" post="leakage in ONNV-infected joints, tracer assay and in vivo"/>
 <result pre="and in vivo imaging were performed. At the peak of" exact="joint swelling," post="a marginal and non-significant increase of tracer dye could"/>
 <result pre="mock-infected controls (Figure 1F). Together, these results show that ONNV" exact="infection" post="does not cause a detectable edema and vascular leakage"/>
 <result pre="that ONNV infection does not cause a detectable edema and" exact="vascular" post="leakage in the joints. High-Dimensional Analysis of Immune Infiltrates"/>
 <result pre="Infiltrates Highlights Involvement of CD4+ T Cells The development of" exact="joint swelling" post="and pathology during ONNV infection could be driven by"/>
 <result pre="Cells The development of joint swelling and pathology during ONNV" exact="infection" post="could be driven by the immune-pathogenesis of infiltrating leukocytes"/>
 <result pre="during ONNV infection could be driven by the immune-pathogenesis of" exact="infiltrating" post="leukocytes into the joints. To characterize the immune-cell profiles"/>
 <result pre="cells in the joint. As observed from the biplots, ONNV" exact="infection" post="resulted in the activation of macrophages (clusters 14, 15,"/>
 <result pre="Red box indicates the upregulated clusters during 6 dpi. (C)" exact="Leukocyte" post="subsets were identified by antibody staining based on lineage"/>
 <result pre="identified by antibody staining based on lineage surface marker expression." exact="Leukocyte" post="subsets in ONNV-infected joints at 6 dpi were quantified,"/>
 <result pre="U-test (**P &amp;lt; 0.01). To quantify the number of cells" exact="infiltrating" post="into the joints upon ONNV infection, cells acquired from"/>
 <result pre="of cells infiltrating into the joints upon ONNV infection, cells" exact="acquired" post="from the flow cytometry were sorted into the major"/>
 <result pre="MHC-II+ monocytes (Figure 2C). CD4+ T Cells Mediate Inflammation and" exact="Muscle" post="Necrosis During Arthritogenic ONNV Infection Since CD4+ T cells"/>
 <result pre="T Cells Mediate Inflammation and Muscle Necrosis During Arthritogenic ONNV" exact="Infection" post="Since CD4+ T cells were shown possess pathogenic roles"/>
 <result pre="CD4+ T cells were shown possess pathogenic roles in multiple" exact="alphavirus infections" post="(16, 21, 26â€&quot;28), we next decided to elucidate their"/>
 <result pre="T cells were shown possess pathogenic roles in multiple alphavirus" exact="infections" post="(16, 21, 26â€&quot;28), we next decided to elucidate their"/>
 <result pre="T cells were infected with ONNV and subsequently monitored for" exact="disease" post="pathogenesis. Absence of CD4+ T cells significantly abrogated the"/>
 <result pre="were infected with ONNV and subsequently monitored for disease pathogenesis." exact="Absence of" post="CD4+ T cells significantly abrogated the severity of peak"/>
 <result pre="addition, histopathological analyses also revealed significantly less inflammation in the" exact="muscle" post="and subcutaneous area, and lower levels of muscle necrosis"/>
 <result pre="significantly less inflammation in the muscle and subcutaneous area, and" exact="lower" post="levels of muscle necrosis (Figures 3C,D). Concordantly, adoptive transfer"/>
 <result pre="in the muscle and subcutaneous area, and lower levels of" exact="muscle" post="necrosis (Figures 3C,D). Concordantly, adoptive transfer of CD4+ T"/>
 <result pre="(Figures 3C,D). Concordantly, adoptive transfer of CD4+ T cells re-established" exact="joint swelling" post="in ONNV-infected TCRâˆ’/âˆ’ animals (Figures 4Aâ€&quot;C). Notably, the introduction"/>
 <result pre="Figure 3 Arthritogenic CD4+ T cells mediate joint pathology. (A)" exact="Joint" post="swelling and (B) viremia of ONNV+CD4 depletion (n ="/>
 <result pre="edema, inflammation in different regions of the joint footpad and" exact="muscle" post="pathology of ONNV-infected mice (n = 6) on 6"/>
 <result pre="of CD4+ T cells into ONNV-infected TCRâˆ’/âˆ’ mice re-establishes virus-induced" exact="joint swelling." post="(A) CD4+ T cells were negatively isolated from spleens"/>
 <result pre="isolated from spleens of ONNV-infected or mock-infected WT C57BL/6 donors." exact="Isolated" post="CD4+ T cells were then transferred into respective groups"/>
 <result pre="of recipient TCRâˆ’/âˆ’ mice (1 spleen to 1 recipient). (B)" exact="Joint" post="swelling and (C) viremia of ONNV-infected recipient TCRâˆ’/âˆ’ mice"/>
 <result pre="U-test (**P &amp;lt; 0.01). Therapeutic Treatment With Fingolimod Alleviates ONNV-Induced" exact="Joint" post="Inflammation by Suppressing Pathogenic CD4+ T Cell Infiltration into"/>
 <result pre="CD4+ T cell infiltration with an FDA-approved drug could reduce" exact="disease" post="phenotype in the virus-infected joint (28). Therefore, we assessed"/>
 <result pre="Î¼g daily from 2 to 6 dpi). Treatment successfully abrogated" exact="joint swelling," post="with no effect on viremia (Figures 5A,B). Figure 5"/>
 <result pre="ONNV-induced joint pathology by inhibiting CD4+ T cells infiltration. (A)" exact="Joint" post="inflammation and (B) viremia of ONNV+FTY720 treated groups and"/>
 <result pre="of [18F]FB-IL-2 uptake in the joints of FTY720-treated mice were" exact="limited" post="to basal levels (2% ID/g), indicating that treatment inhibited"/>
 <result pre="inhibited the infiltration of activated CD4+ T cells into the" exact="infection" post="site (Figure 5D). To confirm this, flow cytometry phenotyping"/>
 <result pre="(Figure 5D). To confirm this, flow cytometry phenotyping of the" exact="infiltrating" post="cells was performed at 6 dpi on the infected"/>
 <result pre="LFA-1+ CD4+ T cells were similar, there was a slightly" exact="lower" post="amount of total CD4+ T cells in the pLN"/>
 <result pre="cells were similar, there was a slightly lower amount of" exact="total" post="CD4+ T cells in the pLN (Figure 5F), suggesting"/>
 <result pre="and may not accurately mirror the host immune response and" exact="disease" post="progression observed in ONNV patients (29). A wild-type C57BL/6J"/>
 <result pre="to the 6WO model in this study, the lack of" exact="joint swelling" post="and detectable viremia is intriguing. This could be due"/>
 <result pre="to establish an in vivo model that can recapitulate virus-induced" exact="disease" post="observed in patients. Nevertheless, pathogenicity of IMTSSA/5163 and SG650"/>
 <result pre="therapeutic and prophylactic strategies. Here, an immune-competent in vivo young" exact="adult" post="mouse model for ONNV infection is reported. When infected"/>
 <result pre="an immune-competent in vivo young adult mouse model for ONNV" exact="infection" post="is reported. When infected with ONNV, animals recapitulated the"/>
 <result pre="(1, 5, 30). ONNV joint pathology was characterized by marked" exact="muscle" post="degeneration and necrosis, mild synovitis, and tenosynovitis around the"/>
 <result pre="characterized by marked muscle degeneration and necrosis, mild synovitis, and" exact="tenosynovitis" post="around the tendon capsule of the infected joint. However,"/>
 <result pre="tenosynovitis around the tendon capsule of the infected joint. However," exact="joint swelling" post="was not associated with edema (Figure 1C). This mirrors"/>
 <result pre="immune-competent mouse model can be appropriately adopted for understanding ONNV" exact="disease" post="pathogenesis and the discovery of therapeutic strategies. High-dimensional UMAP"/>
 <result pre="cells drastically reduced joint footpad swelling, immune cell infiltration and" exact="muscle" post="degeneration and necrosis at 6 dpi (Figures 3A,C,D), with"/>
 <result pre="infiltration suppressive drug could be used to reduce ONNV induced" exact="joint swelling." post="Administration of FTY720 into ONNV-infected joints reduced the joint"/>
 <result pre="joint swelling. Administration of FTY720 into ONNV-infected joints reduced the" exact="joint swelling" post="during the peak of inflammation at 6 dpi (Figure"/>
 <result pre="a large spectrum of arthritogenic alphaviruses. Successful treatment of alphavirus" exact="disease" post="using CTLA4-Ig, an anti-rheumatic drug has also been reported"/>
 <result pre="of such FDA-approved drugs, together with their wide usage against" exact="multiple sclerosis" post="and rheumatoid arthritis, respectively, highlights the interesting possibility of"/>
 <result pre="drugs, together with their wide usage against multiple sclerosis and" exact="rheumatoid arthritis," post="respectively, highlights the interesting possibility of repositioning immune-modulating drugs"/>
 <result pre="CD4+ T cells are upregulated and major contributors in alphavirus-induced" exact="disease" post="in patients. Thus, we propose the use of [18F]FB-IL-2"/>
 <result pre="the identified pathogenic mediator. Similar repositioning of drugs that target" exact="viral" post="protein synthesis, increase viral genome mutational load or decrease"/>
 <result pre="Similar repositioning of drugs that target viral protein synthesis, increase" exact="viral" post="genome mutational load or decrease virus infectivity has previously"/>
 <result pre="decrease virus infectivity has previously been performed successfully for different" exact="viral" post="pathogens, such as dengue virus (33), human immunodeficiency virus"/>
 <result pre="for different viral pathogens, such as dengue virus (33), human" exact="immunodeficiency" post="virus (34) and zika virus (35). In light of"/>
 <result pre="T-HT, AT-R, RC, and F-ML performed the experiments. RR performed" exact="blind" post="histopathological scoring of the virus infected joints. Y-HC, T-HT,"/>
 <result pre="The authors declare that the research was conducted in the" exact="absence of" post="any commercial or financial relationships that could be construed"/>
 <result pre="Prof. Andres Merits and Dr. Age Utt provided the luciferase-tagged" exact="infectious" post="clone used in this project. Funding. This study was"/>
 <result pre="Infect Dis. (1999) 29:1243â€&quot;50. 10.1086/31346210524970 2.ShoreHO'nyong-nyong fever: an epidemic virus" exact="disease" post="in East Africa: III. Some clinical and epidemiological observations"/>
 <result pre="Med Hyg. (1961) 55:361â€&quot;73. 10.1016/0035-9203(61)90106-7 3.WilliamsMCWoodallJPO'nyong-nyong fever: an epidemic virus" exact="disease" post="in East Africa. Trans R Soc Trop Med Hyg."/>
 <result pre="J Trop Med Hyg. (2005) 73:32. 10.4269/ajtmh.2005.73.1.073003216014827 6.SandersEJRwagumaEBKawamataJKiwanukaNLutwamaJJSsengoobaFPet al.. O'nyong-nyong" exact="Fever" post="in South-Central Uganda, 1996â€&quot;1997: description of the epidemic and"/>
 <result pre="Dis. (1999) 180:1436â€&quot;43. 10.1086/31507310515801 7.KamYWPokKYEngKETanLKKaurSLeeWWLet al.. Sero-prevalence and cross-reactivity of" exact="chikungunya" post="virus specific anti-E2EP3 antibodies in arbovirus-infected patients. PLoS Negl"/>
 <result pre="Dis. (2015) 9:e3445. 10.1371/journal.pntd.000344525568956 8.WilliamsMCWoodallJPPorterfieldJS. O'nyong-nyong fever: an epidemic virus" exact="disease" post="in East Africa: V Human antibody studies by plaque"/>
 <result pre="56:166â€&quot;72. 10.1016/0035-9203(62)90144-X14038061 9.LaBeaudADBandaTBrichardJMuchiriEMMungaiPLMutukuFMet al.. High rates of o'nyong nyong and" exact="chikungunya" post="virus transmission in coastal kenya. PLoS Negl Trop Dis."/>
 <result pre="12.KamY-WLeeWWLSimarmataDHarjantoSTengT-STolouHet al.. Longitudinal analysis of the human antibody response to" exact="chikungunya" post="virus infection: implications for serodiagnosis and vaccine development. J"/>
 <result pre="al.. Inhibitors of alphavirus entry and replication identified with a" exact="stable" post="chikungunya replicon cell line and virus-based assays. PLoS ONE."/>
 <result pre="Inhibitors of alphavirus entry and replication identified with a stable" exact="chikungunya" post="replicon cell line and virus-based assays. PLoS ONE. (2011)"/>
 <result pre="assays. PLoS ONE. (2011) 6:e28923. 10.1371/journal.pone.002892322205980 14.ChanYTeoTUttATanJJAmrunSNAbu BakarFet al.. Mutating" exact="chikungunya" post="virus non-structural protein produces potent live-attenuated vaccine candidate. EMBO"/>
 <result pre="Mol Med. (2019) 11:e10092. 10.15252/emmm.20181009231015278 15.PlaskonNEAdelmanZNMylesKM. Accurate strand-specific quantification of" exact="viral" post="RNA. PLoS ONE. (2009) 4:e7468. 10.1371/journal.pone.000746819847293 16.TeoTHLumFMClaserCLullaVLullaAMeritsAet al.. A"/>
 <result pre="16.TeoTHLumFMClaserCLullaVLullaAMeritsAet al.. A pathogenic role for CD4+ T cells during" exact="chikungunya" post="virus infection in mice. J Immunol. (2013) 190:259â€&quot;69. 10.4049/jimmunol.120217723209328"/>
 <result pre="al.. A pathogenic role for CD4+ T cells during chikungunya" exact="virus infection" post="in mice. J Immunol. (2013) 190:259â€&quot;69. 10.4049/jimmunol.120217723209328 17.BechtEMcInnesLHealyJDutertreCAKwokIWHNgLGet al.Dimensionality"/>
 <result pre="A pathogenic role for CD4+ T cells during chikungunya virus" exact="infection" post="in mice. J Immunol. (2013) 190:259â€&quot;69. 10.4049/jimmunol.120217723209328 17.BechtEMcInnesLHealyJDutertreCAKwokIWHNgLGet al.Dimensionality"/>
 <result pre="arXiv. (2018) 3:180203426. 10.21105/joss.00861 20.HartimathSVDraghiciuOvan de WallSManuelliVDierckxRAJONijmanHWet al.Noninvasive monitoring of" exact="cancer" post="therapy induced activated t cells using [18f]fb-il-2 pet imaging."/>
 <result pre="[18f]fb-il-2 pet imaging. Oncoimmunology. (2017) 6:e124801410.1080/2162402X.2016.124801428197364 21.CarissimoGTorres-RuestaAChanY-HLeeBFongS-WChuaT-Ket al.. Viperin controls" exact="chikungunya" post="virusâ€&quot;specific pathogenic T cell IFNÎ³ Th1 stimulation in mice."/>
 <result pre="Alliance. (2019) 2:e201900298. 10.26508/lsa.20190029830665948 22.TeoT-HHerZTanJJLLumFLeeWWLChanY-Het al.. Caribbean and la rÃ©union" exact="chikungunya" post="virus isolates differ in their capacity to induce proinflammatory"/>
 <result pre="capacity to induce proinflammatory Th1 and NK cell responses and" exact="acute" post="joint pathology. J Virol. (2015) 89:7955â€&quot;69. 10.1128/JVI.00909-1525995257 23.MorrisonTEOkoLMontgomerySAWhitmoreACLotsteinARGunnBMet al.."/>
 <result pre="Virol. (2015) 89:7955â€&quot;69. 10.1128/JVI.00909-1525995257 23.MorrisonTEOkoLMontgomerySAWhitmoreACLotsteinARGunnBMet al.. A mouse model of" exact="chikungunya" post="virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis,"/>
 <result pre="J Pathol. (2011) 178:32â€&quot;40. 10.1016/j.ajpath.2010.11.01821224040 24.CarissimoGNgLFP. Understanding molecular pathogenesis with" exact="chikungunya" post="virus research tools. Curr Top Microbiol Immunol. (2019) 10.1007/82_2019_15830888547"/>
 <result pre="al.. Therapy with CTLA4-Ig and an antiviral monoclonal antibody controls" exact="chikungunya" post="virus arthritis. Sci Transl Med. (2017) 9:eaah3438. 10.1126/scitranslmed.aah343828148840 27.RowellJFGriffinDE."/>
 <result pre="encephalomyelitis. J Neuroimmunol. (2002) 127:106â€&quot;14. 10.1016/S0165-5728(02)00108-X12044981 28.TeoTChanYLeeWWLLumFAmrunSNHerZet al.Fingolimod treatment abrogates" exact="chikungunya" post="virus-induced arthralgia. Sci Transl Med. (2017) 1333:1â€&quot;12. 10.1126/scitranslmed.aal1333 29.SeymourRLRossiSLBergrenNAPlanteKSWeaverSC."/>
 <result pre="versus adaptive immune responses in a mouse model of O'Nyong-Nyong" exact="virus infection." post="Am J Trop Med Hyg. (2013) 88:1170â€&quot;9. 10.4269/ajtmh.12-067423568285 30.RwagumaEBLutwamaJJSempalaSDKKiwanukaNKamugishaJOkwareSet"/>
 <result pre="Emergence of epidemic O'nyong-nyong fever in southwestern Uganda, after an" exact="absence of" post="35 years. Emerg Infect Dis. (1997) 3:77. 10.3201/eid0301.9701129126450 31.FraserJR."/>
 <result pre="of 35 years. Emerg Infect Dis. (1997) 3:77. 10.3201/eid0301.9701129126450 31.FraserJR." exact="Epidemic" post="polyarthritis and ross river virus disease. Clin Rheum Dis."/>
 <result pre="ChuJJHet al.. Drug repurposing of quinine as antiviral against dengue" exact="virus infection." post="Virus Res. (2018) 255:171â€&quot;8. 10.1016/j.virusres.2018.07.01830055216 34.ClouserCLPattersonSEManskyLM. Exploiting drug repositioning"/>
</results>
